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AbstrAct
Introduction Primary sclerosing cholangitis (PSC) is a 
progressive inflammatory liver disease characterised by 
relentless liver fibrosis and a high unmet need for new 
therapies. Preventing fibrosis represents an important area 
of interest in the development of vital new drugs. Vascular 
adhesion protein-1 (VAP-1) drives inflammation in liver 
disease, and provision of an antibody against VAP-1 blunts 
fibrosis in murine models of liver injury.
Methods and analysis BUTEO is a single-arm, two-stage, 
open-label, multi-centre, phase II clinical trial. Up to 59 
patients will receive treatment with anti-VAP monoclonal 
antibody, BTT1023, over a 78-day treatment period. Adults 
with PSC and a serum alkaline phosphatase (ALP) of at 
least 1.5 times the upper limit of normal will be included. 
Our primary outcome measure is a reduction in ALP by 
>25% from baseline to Day 99. Secondary outcome 
measures include safety and tolerability, changes pre 
therapy/post therapy in circulating serum VAP-1 as well as 
imaging findings. The first patient participant was recruited 
on 08 September 2015.
Ethics and dissemination This protocol has been 
approved by the Research Ethics Committee (REC, 
reference 14/EM/1272). The first REC approval date 
was 06 January 2015 with three subsequent approved 
amendments. This article refers to protocol V3.0, dated 
16 March 2016. Results will be disseminated via peer-
reviewed publication and presentation at international 
conferences.
Trial registration The trial is registered with the European 
Medicines agency (EudraCT: 2014-002393-37), the 
National Institute for Health Research (Portfolio ID: 18051) 
and ISRCTN: 11233255. The  clinicaltrials. gov identifier is 
NCT02239211. Pre-results.
IntroductIon
End-stage liver disease, regardless of aeti-
ology, is characterised by progressive hepatic 
fibrosis culminating in liver cirrhosis and 
accompanying increased risks of liver 
cancer, liver failure, portal hypertension and 
death. Preventing progressive liver fibrosis 
represents an important area of interest in 
the development of new drugs suitable for 
all patients with liver disease. Primary scle-
rosing cholangitis (PSC) is a prime example 
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Protocol
Strengths and limitations of this study
 ► Unique, tailor-made clinical trial design incorporating 
a dose confirmatory and safety stage (based on the 
traditional 3+3 design), then followed by a phase II 
Simon’s two-stage design.
 ► Brings the translation of laboratory research into a 
proof of activity clinical trial.
 ► An early-phase experimental medicine study of a 
novel first-in-class drug, in a chronic disease cohort 
with a large unmet need for new therapies.
 ► Aims to address not just the need for new therapies 
but also the need for reliable clinical trial endpoints 
as well as biomarkers for staging and predicting 
clinical outcomes.
 ► Small cohort due to primary sclerosing 
cholangitis being a rare orphan disease as well as 
unpredictability of the  disease making stability for 
clinical trial inclusion difficult.
 ► Short duration of the treatment period in which goal 
is to demonstrate collective markers of efficacy to 
justify longer and placebo-controlled trials.
 ► Limited evidence base for the primary endpoint of 
a reduction in alkaline phosphatase in the context 
of anti-fibrotic agents, however accepting that there 
is no alternative surrogate currently available.
 ► Translational study from mice into human subjects 
and the unknown differences this may entail.
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of a progressive inflammatory liver disease which is char-
acterised by persistent liver fibrosis and a high unmet 
need for new therapies. PSC has a population incidence 
of 1.3 per 100 000 annually, with a prevalence of 16.2 
per 100 000.1 2 3 It affects both men and women, with a 
median age of 41 years,4 and is associated with inflam-
matory bowel disease (IBD) in 80% of cases.5 More than 
50% of patients require liver transplantation within 
10–15 years of symptomatic presentation,6 7 reflecting 
the failure of medical therapies to have any impact on 
the clinical outcome: in the UK, for example, PSC is 
now the leading autoimmune liver disease indication 
for transplant, despite being the rarest of the autoim-
mune liver diseases. One barrier to the development 
of efficacious new medical therapies is the lack of clin-
ically relevant endpoints and there is an urgent need to 
develop appropriate non-invasive surrogate endpoints to 
improve clinical trial design.8
Vascular adhesion protein-1 (VAP-1)
Vascular adhesion protein-1 (VAP-1) is a 170-kDa homod-
imeric type 2 transmembrane sialoglycoprotein with a 
short cytoplasmic tail of no known signal sequence, a 
single transmembrane segment and a large extracellular 
domain. VAP-1 is constitutively expressed on human 
hepatic endothelium and supports lymphocyte adhe-
sion and transendothelial migration. Cloning of VAP-1 
revealed it to be a copper-dependent semicarbazide-sen-
sitive amine oxidase (SSAO) which catalyses the oxidative 
deamination of exogenous and endogenous primary 
amines resulting in the generation of aldehyde, ammonia 
and H2O2. These products activate NFκB-dependent 
chemokine secretion and adhesion molecule expression 
in liver endothelium and may initiate and propagate 
oxidative stress following the conversion of H2O2 to 
hydroxyl free radicals. A soluble form of VAP-1 (sVAP-1) 
accounts for nearly all of the circulating amine oxidase 
activity in humans. 9
The progression of PSC to scarring, cirrhosis and 
hepatobiliary cancer is driven by a chronic inflammatory 
response and immune cell mediated destruction of bile 
ducts.10 Our research implicates VAP-1 in the inflam-
mation that drives fibrogenesis in liver disease.11 VAP-1 
also acts as an adhesion receptor to support leucocyte 
recruitment in liver inflammation, a function that is crit-
ical in animal models in the formation of fibrosis.12 Thus, 
inhibition of VAP-1 is expected to impact both inflam-
mation and fibrosis; indeed, treatment with an antibody 
against VAP-1 prevents fibrosis in murine models of liver 
injury.9 Data also shows particularly high levels of circu-
lating serum VAP-1 (sVAP-1) in patients with PSC as well 
as a strong correlation between sVAP-1/SSAO activity in 
serum and histological fibrosis scores in patients with 
fatty liver disease.9 Based on the strong up-regulation 
of hepatic VAP-1 reported in PSC patients,9 we hypoth-
esise that levels of sVAP-1/SSAO will correlate with the 
severity of fibrosis in PSC and will predict patients at risk 
of progressive disease.
These observations underpin our proposal that VAP-1 
has an important role in the progression of liver fibrosis. 
We now plan to test the hypothesis that inhibiting VAP-1 
with a neutralising antibody (BTT1023) will reverse or 
delay fibrogenesis in patients with PSC. Additionally, 
reliable biomarkers that correlate with fibrosis stage and 
progression of liver disease are in demand in order to 
predict outcome and to stage disease, without the need 
for invasive liver biopsy. This research will allow us to trans-
late laboratory research into a proof of activity clinical 
trial that will elucidate the role of VAP-1 in liver fibrosis 
and its potential as a therapeutic target and biomarker.
Btt1023 (now known as timolumab)
BTT1023 is a fully human, monoclonal, anti-VAP-1 
antibody which blocks the adhesion function of VAP-1, 
thereby diminishing leucocyte entry into sites of tissue 
inflammation. Going forward, BTT1023 will be known 
as Timolumab; however, the original numeric name is 
used in this manuscript in order to remain in keeping 
with the trial protocol. In vivo, blocking VAP-1 function 
with an anti-mouse anti-VAP-1 antibody significantly alle-
viates inflammation in mouse models of arthritis and liver 
fibrosis.13 BTT1023 appears to be safe and well tolerated 
in humans: BTT1023 has been given in doses up to 8 mg/
kg in patients with rheumatoid arthritis and psoriasis after 
oral premedication (cetirizine and ibuprofen) and also 
appears safe and well tolerated in repeated intravenous 
dosing.14 No cytokine release syndrome was seen. This 
dose therefore appears reasonable as a starting point 
and is considered to provide appropriate bridging into 
existing clinical data.
In the well-tolerated arthritis study, patients received 5 
doses at fortnightly intervals with potentially efficacious 
trough levels being achieved by Day 42, after 3 doses. The 
psoriasis study used a more rapid loading of 3 doses at 
Days 1, 8 and 22, which was also well tolerated. Therefore, 
we have decided to deploy the accelerated dosing scheme 
(ie, dosing on Days 1 and 8 and biweekly thereafter) in 
the current study.14
BTT1023 is produced in a Chinese hamster ovary cell 
culture and purified with appropriate methods including 
specific viral inactivation and removal procedures. 
BTT1023 is contained in single-use 100 mg/10 mL glass 
vials and requires dilution with BTT1023 IV Infusion 
Diluent (0.9% sodium chloride and 0.02% polysorbate 
80 in water for injection) prior to administration by intra-
venous infusion. The amount of diluent to be added to 
the BTT1023 concentrate is calculated to consistently 
provide a total diluted drug product infusion volume of 
50 mL. BTT1023 and its diluent are stored at 2–8°C and 
the maximum shelf life for the diluted infusion solution 
is 24 hours when stored at this temperature.
objectives
The trial primary objective is to determine the activity 
of the anti-VAP-1 antibody BTT1023 in patients with 
PSC as measured by a decrease in alkaline phosphatase 
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(ALP) levels (primary endpoint) with secondary endpoints 
to include various measures of liver injury and fibrosis 
and evaluation of the safety, effective dose and tolerability 
of BTT1023 in patients with PSC. Our secondary objec-
tives include determining the mechanisms of action of 
BTT1023 through in vitro assessment of sVAP-1 concen-
tration, SSAO enzyme activity and immune cell function; 
evaluating the potential of a novel MRI-based assessment 
of liver fibrosis and biliary strictures for assessing thera-
peutic response in PSC; and assessing the use of sVAP-1/
SSAO as a biomarker to monitor disease progression in 
PSC.
Methods
study design overview
BUTEO is a two-stage single-arm, open-label, multi-centre 
hybrid trial of treatment with monoclonal anti-VAP-1 anti-
body, BTT1023, in adult patients with PSC. The sample 
size will be a maximum of 59 patients, who will each have 
up to 7 intravenous infusions of BTT1023 over a 78-day 
treatment period. All patients will be followed up until 
Day 120 (42 days after the last administration of treat-
ment). At specified time points during each visit, serum 
will be taken for circulating levels of BTT1023 as well as 
for anti-drug antibodies, VAP-1 activity and additional 
exploratory research samples. This includes pre dose, 
during dose and post dose, with some patients also 
attending 24 hours later for further blood testing.
The trial is composed of two components. The run-in 
component of the trial incorporates a conventional 3+3 
cohort design to confirm the therapeutic dose, with 
decisions regarding continuation based on toxicity and 
pharmacokinetic (PK) data, figure 1. The trial begins 
with the recruitment of 6 patients all receiving the starting 
dose of 8 mg/kg. Recruitment will be paused while 
awaiting the results of trough blood serum levels of circu-
lating BTT1023 at Visit 7 (Day 50) from all 6 patients and 
until the dose-limiting toxicity (DLT) reporting period is 
completed for each patient (Visit 10 [Day 99]).
If results from the first cohorts show an acceptable DLT 
rate (see later) and trough levels of BTT1023 meet the 
stipulated success criteria, the trial will continue into the 
expansion component of the trial. Acceptable trough 
levels have been set a trough concentration of 3 μg/
mL free circulating BTT1023 at 8 weeks from first infu-
sion, which is approximately 100-fold the dissociation 
constant (Kd) of BTT1023 from VAP-1 and will result in 
target occupancy of approximately 90%. In the event that 
DLT rate is acceptable but the PK levels do not meet the 
success criteria, then the trial moves into a conventional 
3+3 cohort design, using escalating doses of BTT1023. 
In this event, the original cohort of 6 patients will no 
longer be evaluated, but a new cohort of 3 patients will 
be recruited to receive the newly identified test dose of 
12 mg/kg. If there are no DLTs at Visit 10 [Day 99], an 
additional cohort of 3 patients will be recruited at the new 
test dose. If the DLT rate remains acceptable but the PK 
levels still do not meet the success criteria, a further 3+3 
patients will be recruited at the highest dose of 16 mg/kg. 
If this is found not to result in sufficient blood levels of 
BTT1023, then the trial will be stopped. If the PK values 
are found to be too high (such as resulting in trough 
levels consistently exceeding 100 μg/mL), then there is 
potential to de-escalate the dose in agreement with the 
Data Monitoring Committee (DMC) and after regulatory 
approvals. The trial will be stopped at any stage where 
patient safety is compromised. Individual patients will 
only receive one dose level. Once a confirmed dose has 
been established, the trial will expand until a total of 37 
patients have received treatment with the confirmed dose, 
including those patients who have previously received 
this dose during the confirmatory period. Those patients 
not receiving the confirmed dose will not be included in 
the final evaluation.
Patient selection
Patients with particularly elevated ALP levels are predicted 
to be more at risk of progressive disease; thus, these 
patients will be selected. Currently, four UK academic 
hospital centres are involved (based in Birmingham, 
Nottingham, Oxford and Newcastle) with further centres 
potentially coming on board shortly. Informed consent 
will be obtained by appropriately trained members of the 
research team at each site.
The main inclusion criteria are patients aged 
18–75 years with a clinical diagnosis of PSC, as evidenced 
by chronic cholestasis of more than 6 months duration 
with either an MRI or liver biopsy consistent with PSC 
and in the absence of a documented alternative aetiology. 
Patients must have an ALP of at least 1.5 times the upper 
limit of normal. Those with concomitant IBD must have 
evidence to show clinically and colonoscopically stable 
disease within the past 12 months, without findings of 
high-grade dysplasia and without the need for biological 
therapies. In those on treatment with ursodeoxycholic 
acid (UDCA), therapy must be stable for at least 8 weeks 
prior to screening and at a dose not greater than 20 mg/
kg per day. In those not on treatment with UDCA at the 
time of screening, a minimum of 8 weeks since the last 
dose of UDCA should be recorded. As an IgG molecule, 
BTT1023 is not anticipated to interfere with chromo-
somal material; however, teratogenicity has not been 
studied and so rigorous steps will be taken to exclude 
pregnancy pre-treatment and with regard to need for 
effective contraception throughout the trial and for 99 
days after. Some of the main exclusion criteria can be 
seen in box 1.
treAtMent
A single-arm, rather than placebo-controlled, design was 
chosen to allow efficient enrolment of patients into the 
study due to its intensive nature, in which a significant 
chance of being allocated into the placebo group may 
act as a substantial barrier for enrolment. The proposed 
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Figure 1 Flow diagram showing the trial decision guidelines for the run-in period of the trial design, incorporating a 
conventional 3+3 cohort design if dose escalation is required.
primary endpoint (ALP) is a biochemical measurement 
and thus not open to subjective bias as a clinical assess-
ment would be, rendering the necessity of a concurrent 
control group less vital.
trIAl scheMA
Given the unpredictable nature of PSC and natural 
variation of ALP levels, we have built into the trial a 
two-stage screening process over 4–7 weeks, whereby the 
ALP levels must not vary by more than 25% in order to 
continue to enrolment. During screening, patients have 
routine blood screens and other non-invasive markers 
of liver fibrosis including Mayo PSC Risk Score, MELD, 
Enhanced Liver Fibrosis (ELF), Fibroscan and MRCP 
with additional LiverMultiscan imaging. These will then 
be repeated during treatment and in the follow-up period 
to assess for any change.
During all 7 treatment visits, patients will receive 
pre-medication with cetirizine 10 mg + ibuprofen 400 
mg orally (in the absence of any contraindications) 
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Box 1 Main exclusion criteria (not a complete list)
 ► AST and ALT >10xULN or bilirubin >3xULN or INR >1.3 in the 
absence of anti-coagulants.
 ► Serum creatinine >130 μmol/L or platelet count <50 x 109/L.
 ► Any evidence of hepatic decompensation past or present, including 
ascites, hepatic encephalopathy or variceal bleeding.
 ► Recent cholangitis within last 90 days or ongoing need for 
prophylactic antibiotics.
 ► Pregnancy or breast feeding.
 ► Flare in colitis activity within last 90 days requiring intensification 
of therapy beyond baseline maintenance treatment; use of oral 
prednisolone >10 mg/day, biologics (ie, monoclonal antibodies) and 
or hospitalisation for colitis within 90 days. Prior use of biologics is 
not a contraindication to screening.
 ► Diagnosed cholangiocarcinoma or high clinical suspicion of 
cholangiocarcinoma.
 ► Concurrent malignancies or invasive cancers diagnosed within past 
3 years except for adequately treated basal cell and squamous cell 
carcinoma of the skin and in situ carcinoma of the uterine cervix.
 ► Presence of a percutaneous drain, bile duct stent or prior organ 
transplantation.
 ► Participation in an investigational trial of a drug or device within 60 
days of screening or 5 half-lives of the last dose of investigational 
drug.
 ► Positive screening test for tuberculosis (TB) (including T-SPOT.TB TB 
test), unless respiratory review confirms false-positive test results.
 ► Receipt of live vaccination within 6 weeks prior to baseline visit.
plus intravenous hydrocortisone 100 mg, 1–2 hours pre 
infusion (the latter for the first 3 doses only). The first 
infusion will be given over 2 hours, with a 4-hour moni-
toring period post infusion. Provided that no adverse 
reactions are seen, the infusion time will drop to 1 hour 
with initially a 3-hour observation period (for the second 
dose) and then down to 2 hours monitoring post infu-
sion (for all subsequent doses). Safety investigations will 
be completed pre infusion and post infusion and they 
include haematology/biochemistry sampling, along with 
ECG, clinical assessment and physical examination. The 
full trial schema can be seen as figure 2.
A aliquot (0.5–1.0 mL) of the BTT1023 infusion 
solution will be taken at the end of every infusion and 
refrigerated. These samples may be used for analysis 
of BTT1023 concentration if anomalies in PK data are 
observed that could be due to errors in IMP preparation.
data analysis plan
Power calculations and sample size justification
The dose confirmatory stage requires a maximum of 18 
patients. The sample size has been based on the classic 
3+3 design, investigating three fixed dose increments (8, 
12 and 16 mg/kg), with no dose skipping.
The expansion phase follows a Simon’s two-stage 
minimax design with lower and upper acceptability 
bounds of 15% and 30%, respectively, and error rates 
α=0.10 and β=0.20. Thirty-seven patients are required 
in this stage of the trial; however, to account for patient 
dropout, estimated at approximately 10%, the sample 
size is extended by a further 4 patients. As such, the target 
recruitment is up to 41 patients for the expansion phase 
and up to 59 participants in total. An interim assessment 
will examine the primary outcome once 18 evaluable 
patients have been recruited at the confirmed dose. If 3 
or more responses are observed in stage 1, then the trial 
will continue into stage 2. Recruitment will not be halted 
while stage 1 is assessed. If the stage 1 criterion is not met, 
then the trial will cease. However, if the criterion is met, 
then further patient recruitment continues until 37 eval-
uable patients are recruited. If overall there are 9 or more 
responses from 37 evaluable patients, then we conclude 
that the treatment warrants further investigation.
In this setting, the interpretation of alpha (α) is the 
probability satisfying stage 1 and observing 9 or more 
responses in 37 patients overall when the true response 
rate is 15%; a false-positive result (type 1 error). Beta (β) 
is the probability of failing to acknowledge activity when 
the true response rate is 30% (type 2 error). As such, the 
power, 1−β, is the probability of taking an effective treat-
ment forward.
outcoMe MeAsures And AnAlysIs
This is an early-phase trial of BTT1023 in immune cell 
mediated liver disease, with the rationale to identify 
biochemical efficacy (reduction in ALP) and safety, in 
an orphan disease that presently lacks any other effec-
tive medical therapy. The trial design therefore focuses 
on identifying early biochemical efficacy signals to justify 
larger-scale, randomised controlled trials of a longer 
duration.
Our primary outcome measure is patient response to 
treatment at Day 99, and it is a reduction in serum ALP 
by 25% or more from baseline to Day 99. Our data on 
stability of ALP in PSC suggests that such responses occur 
very seldom during the natural course of the disease, 
and we can therefore reliably assess changes from base-
line and response rates for this proof of concept study to 
evaluate the therapeutic potential of BTT1023. In addi-
tion, we are excluding patients in whom the levels change 
significantly naturally by >25% in the 5-week to 7-week 
screening period.
Secondary outcome measures include safety and toler-
ability via treatment compliance, patient withdrawal, 
frequency of serious adverse event (SAE)/adverse event 
(AE), change in quality of life questionnaires (EQ-5D, 
Fatigue Severity Scale, Pruritus Visual Analogue Score, 
Inflammatory Bowel Disease Diaries) and change in 
quality of BTT1023 efficacy (via tests of liver fibrosis 
including ELF, Fibroscan and liver biochemistry). Addi-
tionally, liver MRI is an emerging method for monitoring 
liver disease and its treatment. We will evaluate changes 
in MRI imaging pre therapy and post therapy using the 
LiverMultiscan protocol (or equivalent methodology, 
at sites where this is possible). Finally, we will evaluate 
changes in sVAP-1/SSAO as a biomarker of liver disease 
activity across the study period.
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Figure 2 BUTEO trial schema.
InterIM AnAlysIs
An interim analysis will be completed once 18 patients 
have been evaluated for the primary outcome (ALP 
response). If 3 or more responses are observed, then the 
trial will continue. If this is not met, then the trial will 
cease. If adequate response is seen, a further 19 patients 
will be recruited in order to obtain the required sample 
size of 37 patients (allowing for 10% patient dropout 
during trial duration, this number could reach a total of 
41 patients recruited). The final success criterion chosen 
maintains power and, in doing so, can incur an increased 
type 1 error rates (note that the stage 1 criterion is fixed 
since the final sample size is unknown at stage 1). These 
have been calculated by the trial biostatistician and inde-
pendently verified by a Cancer Research UK Clinical 
Trials Unit biostatistician.
Patients that cannot be evaluated for the primary 
outcome (eg, due to withdrawal or lost to follow-up) will 
be treated as non-responders.
Final analyses
Final analyses of the primary outcome will be performed 
when all patients have been followed to Day 120 and once 
the database has been locked. If overall there are 9 or more 
responses from 37 evaluable patients, then we conclude 
that the treatment warrants further investigation. Only 
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patients treated at the confirmed dose will contribute to 
the total patient requirement.
conduct oF the trIAl
This is a clinician-initiated and clinician-led trial funded 
by the National Institute for Health Research (NIHR) 
which receives funds directly from the Department of 
Health. Biotie Therapies will be supplying BTT1023 free 
of charge to all individual NHS trusts that will be directly 
treating patients as part of this clinical trial. There are 
payments to individual NHS trusts on a per-patient basis, 
to cover trial running costs. The University of Birmingham 
is acting as trial sponsor and, as such, remains responsible 
for the study conduct.
AdVerse eVent rePortIng
dose-limiting toxicity
Dose-limiting toxicity (DLT) is defined as an AE that 
meets the criteria of grade 3 cytokine release syndrome 
or grade 4/5 for any criteria, as defined in the Common 
Terminology Criteria for Adverse Events (CTCAE V4.0). 
Although previous studies have shown no DLTs with 
BTT1023, toxicity monitoring will be ongoing throughout 
the trial and any concerns will be reported to the Trials 
Office within 24 hours of the investigator becoming aware 
of the event. The DLT reporting period is from Visit 3 
(first infusion) to Visit 10 (21 days after last infusion). An 
acceptable DLT rate has been established for the trial as 
a maximum of 1 incidence in 6 patients (~17%). If the 
DLT rate rises to 2 or more, at any stage during the DLT 
reporting period (Visit 3 [Day 1] to Visit 10 [Day 99]), the 
trial will be halted in consultation with the DMC.
Adverse events/serious adverse events
The collection and reporting of AEs will be in accordance 
with the Medicines for Human Use Clinical Trials Regula-
tions 2004 and its subsequent amendments. The CTCAE 
V4.0 criteria will be used to grade each AE. Any pre-ex-
isting conditions will be reported in the medical history 
and will not be reported as an AE unless the condition 
worsens by at least one CTC grade during the trial. The 
reporting period for AEs will commence from the date 
of consent (Visit 1) and will continue until the final 
follow-up visit (Visit 11: Day 120) or alternatively up to 45 
days post last infusion if the patient withdraws from the 
study prior to completion of all 7 study drug infusions. All 
trial patients will continue to receive standard concomi-
tant clinical care throughout the study.
The Sponsor, appropriate regulatory authority (eg, 
Medicines and Healthcare Products Regulatory Agency 
(MHRA)) and the Research Ethics Committee (REC) will 
be informed of all SAEs as required by current regulations. 
An SAE judging to have a reasonable causal relationship 
to the drug will be recorded as a serious adverse reaction 
or a suspected unexpected serious adverse reaction, as 
appropriate, and will be reported to the MHRA and REC 
within 7 days. The independent DMC will also review all 
SAEs.
In the event that a patient or their partner becomes 
pregnant during the SAE reporting period, this will 
be recorded and reported and followed up, subject to 
required patient/partner approvals.
MonItorIng
Independent onsite monitoring will be carried out as 
required following an initial site-specific risk assessment. 
Additional on-site monitoring visits will be triggered, for 
example, by poor Case Report Form (CRF) return, poor 
data quality, low SAE reporting rates, excessive number 
of patient withdrawals or deviations. Any major problems 
identified during monitoring may be reported to the Trial 
Management Group and the Trial Steering Committee 
and the relevant regulatory bodies.
dIscussIon
PSC is a prime example of a progressive inflammatory 
liver disease characterised by relentless liver fibrosis. 
There is a high unmet need for new therapies as no 
currently licensed therapy has been shown to alter the 
natural course of the disease. The progression of PSC to 
scarring, cirrhosis and hepatobiliary cancer is driven by a 
chronic inflammatory response and immune cell medi-
ated destruction of bile ducts. Our research suggests that 
VAP-1 is heavily implicated as a key driver for fibrogenesis 
and, as such, it provides a target for the possible slowing 
or even reversal of the liver damage seen in PSC.
The unpredictability of PSC along with its designation 
as a rare orphan disease pose particular challenges in trial 
design. ALP fluctuates during the natural course of the 
disease which limits its usefulness as a primary endpoint; 
however, it is commonly used as a standard marker of 
PSC disease activity, in the absence of a viable alterna-
tive. Thus, reliable biomarkers that correlate with fibrosis 
stage and progression of liver disease are in demand in 
order to predict outcome and to stage disease without 
the need for invasive liver biopsy, and this trial will aid 
in investigating the role of VAP-1 in liver fibrosis and its 
potential as a therapeutic target and biomarker.
This unique trial design, incorporating a dose confir-
matory and safety stage (based on the traditional 3+3 
design), then followed by a phase II Simon’s two-stage 
design is aimed to determine a safe and well-tolerated 
dose of BTT1023 and the efficacy of this treatment in a 
new disease group.
Screening for this study commenced on 
01 February 2015 with the first patient registered on 
10 September 2015. Recruitment is ongoing.
ethics and dissemination
The trial is being performed in accordance with the 
recommendations guiding physicians in biomedical 
research involving human subjects, adopted by the 48th 
World Medical Association General Assembly as well as 
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the Research Governance Framework for Health and 
Social Care, the applicable UK Statutory Instruments 
(which include the Medicines for Human Use Clinical 
Trials 2004 and subsequent amendments and the Data 
Protection Act 1998) and Guidelines for Good Clinical 
Practice. The protocol has been approved by the REC with 
the reference of 14/EM/1272. The first REC approval 
date was 06 January 2015 with subsequent amendments 
on 18 March 2015 (non-substantial), 27 November 2015 
(substantial) and 16 March 2016 (substantial) also now 
approved. All active sites have obtained local Research 
and Development department approval and are up to 
date with the latest protocol amendment.
Standard regulations for data handling and patient 
confidentiality are being followed, in accordance with the 
1998 UK Data Protection Act. During the trial, patients 
will be identified using only their unique trial number, 
initials and date of birth on the CRF and in correspon-
dence between the Trials Office and the participating site. 
Data quality will be maintained according to recognised 
guidance and will be consistent to the source data. All 
essential trial documentation and source records will be 
securely retained for at least 15 years after the end of the 
trial or following the processing of all biological material 
collected for research, whichever is the latter. Results will 
be disseminated via peer-reviewed publication and presen-
tation at international conferences; additional summaries 
will be provided to patients and patient support groups.
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